AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Redefining Gleason 6 Prostate Cancer Nomenclature: The Surgeon's Perspective

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Morgan Rouprêt

Consulting or Advisory Role: Takeda, Janssen-Cilag, Ipsen, Sanofi, Intuitive Surgical, GlaxoSmithKline, Roche, Lilly, Arquer Diagnostics, MSD

Travel, Accommodations, Expenses: Coloplast, Astellas Pharma

Guillaume Ploussard

Honoraria: Janssen Oncology, Ferring, Ipsen, Astellas Pharma, AstraZeneca, Takeda

Consulting or Advisory Role: Janssen Oncology, Astellas Pharma, Sanofi Pasteur, Ferring, Bayer

No other potential conflicts of interest were reported.